Skip to main content

Anti-Rheumatic Rx

      #EULAR2025 @eular_org update

      #Recommendations #Rheumatoid #Rx

      prof Smolen
      subtle diff between former guidelines

      MTX

      Janet Pope Janetbirdope

      6 months ago
      #EULAR2025 @eular_org update #Recommendations #Rheumatoid #Rx prof Smolen subtle diff between former guidelines MTX+GC 👇 D/C GCs rapidly 👇 If inadequate response 👇 Other csDMARDs are OUT ❎ ✅go to bDMARD or tsDMARD* TsDMARD after safety assessed @RheumNow RecommendatnII https://t.co/yUrLdk6Eg1
      #RA #recommendations #update

      Some recommendations were merged

      For sure some regions will consider
      #Combination #csDMA

      Janet Pope Janetbirdope

      6 months ago
      #RA #recommendations #update Some recommendations were merged For sure some regions will consider #Combination #csDMARDs or Switch to another 👇🤔 #sulfasalazine #leflunomide Depends on access, pt preference, disease activity/severity #EULAR2025 @RheumNow @eular_org https://t.co/QDPcHhvQiV
      Tapering in RA?
      In SORAIRO (n=149), pts in remission on ozoralizumab+MTX:
      🧪 49% became MTX-free
      ⏱ 80% spaced OZR to

      Jiha Lee JihaRheum

      6 months ago
      Tapering in RA? In SORAIRO (n=149), pts in remission on ozoralizumab+MTX: 🧪 49% became MTX-free ⏱ 80% spaced OZR to q8w CDAI ≤10 maintained in >90% if baseline remission + albumin >3.8 LB0006 @RheumNow #EULAR2025
      #EULAR2025 Abstr#POS1293 Our cohort study support non-medical switch from Rituximab originator to Biosimilar(RTX-B) or b

      Md Yuzaiful Md Yusof Yuz6Yusof

      6 months ago
      #EULAR2025 Abstr#POS1293 Our cohort study support non-medical switch from Rituximab originator to Biosimilar(RTX-B) or btw RTX-Bs in connective tissue disease. No difference in response/B-cell depletion pre- & post-switch.Only 10% stopped RTX at 5-year.Better than in RA @RheumNow https://t.co/ERPgwQ3gZB
      RepurpSS-II RCT (n=46): LEF + HCQ significantly improved systemic disease activity (ESSDAI -4.13) vs PBO in primary #Sj?

      Mrinalini Dey DrMiniDey

      6 months ago
      RepurpSS-II RCT (n=46): LEF + HCQ significantly improved systemic disease activity (ESSDAI -4.13) vs PBO in primary #Sjögrens. ⭐️🌱STAR/CRESS response rates also favoured active treatment. Safe, accessible, affordable option for active disease. @RheumNow #EULAR2025 #LB0005
      🦵🏻SAP-001, a novel uricosuric targeting a non-URAT1 renal transporter, lowered sUA <6 mg/dL in up to 79% of p

      Mrinalini Dey DrMiniDey

      6 months ago
      🦵🏻SAP-001, a novel uricosuric targeting a non-URAT1 renal transporter, lowered sUA <6 mg/dL in up to 79% of patients with refractory #gout on b/g xanthine oxidase inhibitor. >50% on 60 mg/day reached sUA <3 mg/dL. 💊Potential new oral ULT option. @RheumNow #EULAR2025 #LB0008 https://t.co/dfY1V5sHSh
      Management and prognosis of RP by @Lupusreference
      1. Pts with mild disease respond to GCs
      2. NSAIDs/colchicine good alt

      Adela Castro AdelaCastro222

      6 months ago
      Management and prognosis of RP by @Lupusreference 1. Pts with mild disease respond to GCs 2. NSAIDs/colchicine good alternatives 3. Most common biologics used: TNFi and IL6i 4. Consider CYP in life threatening dz/ICU pts 5. Dynamic CT assess tracheal collapse. 6. PET-CT can ≠ https://t.co/PNUecMZvkT
      #EULAR2025 Abstr#POS0301 Real World Multicentre study in Italy reported higher proportion of CRR at 6-mth & Lower GC

      Md Yuzaiful Md Yusof Yuz6Yusof

      6 months ago
      #EULAR2025 Abstr#POS0301 Real World Multicentre study in Italy reported higher proportion of CRR at 6-mth & Lower GC in people with #lupus nephritis (~96% Class III, IV or Mixed with V) treated with Belimumab+SOC vs matched cohort on SOC. Predicted by early BEL use @RheumNow https://t.co/D6e2qo9NRL
      New ideas in gout management
      • EurekAlert!
      Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown.
      Highlights from today included presentations on imaging in vasculitis, a debate on whether to treat high risk pre-clinical RA, and EULAR Recommendations on a) Treatment of interstitial lung disease (ILD); b) Physical Activity in people with arthritis; and c) EULAR disease activity score for antiphospholipid syndrome and d) the management of SLE nephritis. Below are a few others that caught my eye today.
      NMA of 14RCTs (>2500 pts) eval relative efficacy of bDMARDs and tsDMARDs in mostly biologic naïve nr-axSpA pts.
      -All

      Adela Castro AdelaCastro222

      6 months ago
      NMA of 14RCTs (>2500 pts) eval relative efficacy of bDMARDs and tsDMARDs in mostly biologic naïve nr-axSpA pts. -All therapies studied significantly improved ASAS40 response rates compared to placebo. -Certolizumab and Golimumab were the most effective therapies, followed by https://t.co/BJLRpEDYrv
      In 631 axSpA pts (mean age 33y, 54% female) from DESIR cohort, high-dose NSAID use (ASAS NSAID index ≥50) not associat

      Antoni Chan MD (Prof) synovialjoints

      6 months ago
      In 631 axSpA pts (mean age 33y, 54% female) from DESIR cohort, high-dose NSAID use (ASAS NSAID index ≥50) not associated with incident hypertension (HR 1.01; 95% CI 0.98–1.02) over 72 months. NSAID anti-inflammatory effect may offset BP risk in axSpA. Abstract#POS0256 @RheumNow https://t.co/ELYWoJDyKJ
      #Shingrix #vaccination is Impt in #SLE
      HZ vaccination works in SLE, safe – 1yr still good humeral & cellular immun

      Janet Pope Janetbirdope

      6 months ago
      #Shingrix #vaccination is Impt in #SLE HZ vaccination works in SLE, safe – 1yr still good humeral & cellular immunity -attenuation over 1 yr re #immune #responses No major flares #shingles is ⬆️ in #lupus 👇 abnormal immune response #pred, #MMF #IS POS1005 #EULAR2025 @RheumNow https://t.co/o8lDXgOhE1
      How does #HCQ work in #SLE

      Stabilizes lysomal membranes?

      #Lupus pts on HCQ monoRx & low #SLEDAI were followed

      Si

      Janet Pope Janetbirdope

      6 months ago
      How does #HCQ work in #SLE Stabilizes lysomal membranes? #Lupus pts on HCQ monoRx & low #SLEDAI were followed Single cell seq HCQ cytokine sigs May vary over time IFN & OXPosph pathways #Hydroxychloroquine in #LN - #IFN I&II #EULAR2025 @RheumNow POS0983 https://t.co/0gMQh9MNlg
      ×